- September 13, 2022
- 3:00 PM - 4:00 PM ET
Yale University – Mayo Clinic CERSI
Molly M. Jeffery, Ph.D.
Scientific Director of Emergency Medicine Research and Platform Knowledge Solutions
Assistant Professor Health Services Research and Emergency Medicine
About the Presentation
Opioid analgesics are often used to treat moderate-to-severe acute non-cancer pain; however, there is little high-quality evidence to guide clinician prescribing. Many studies report the efficacy of opioids for acute pain, but few address the ideal dose and duration of treatment for various types of pain. The Acute Pain Pathways study was launched in collaboration with and supported by the FDA to understand the trajectories of pain and treatments experienced by a diverse group of opioid naïve patients who are prescribed an opioid analgesic for acute pain. We use a digital health-based patient-centered data aggregation platform to prospectively collect information on the experiences of more than 1500 patients receiving primary and urgent care, emergency care, surgical care, or dental care in five healthcare systems and several community dental practices. In this talk, Dr. Jeffery described the study and presented some preliminary results drawing from participants' reports of their pain severity and resolution, treatments used, satisfaction with care, and opioid handling and safety.
About the Presenter
Molly Moore Jeffery, PhD, MPP, is an assistant professor of Health Services Research and Emergency Medicine at Mayo Clinic in Rochester, Minnesota. Dr. Jeffery is the co-PI of the Yale-Mayo Clinic CERSI. She serves as the Scientific Director of Emergency Medicine Research and Platform Knowledge Solutions. A health services researcher and health economist, Dr. Jeffery’s research interests include treatments for acute and chronic pain, healthcare use in acute care settings, and the use of secondary data to answer important clinical and public health questions. She is the principal investigator for the Acute Pain Pathways study.
Play recording (59 mins)
For Questions and Reasonable Accommodations:
Please contact LaToya Richardson at Latoya.Richardson@fda.hhs.gov.